GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (FRA:PI3) » Definitions » Notes Receivable

Gubra AS (FRA:PI3) Notes Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Notes Receivable?

Gubra AS's Notes Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Gubra AS Notes Receivable Historical Data

The historical data trend for Gubra AS's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Notes Receivable Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

Gubra AS Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Gubra AS Notes Receivable Related Terms

Thank you for viewing the detailed overview of Gubra AS's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Gubra AS Business Description

Traded in Other Exchanges
Address
Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.

Gubra AS Headlines

No Headlines